As the number of immunosuppressive drugs has grown, so has the number of patients referred to gastroenterologists with hepatitis B reactivation, which can lead to acute liver failure. For patients ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... particularly B-cell depleting agents like rituximab, or disease. HBsAg-positivity also confers ...

A role for rituximab in depleting B cells and compromising their antigen ... Type II mixed essential CRYOGLOBULINEMIA (MEC) is often associated with hepatitis C virus (HCV) infection, and leads ...

Patients receiving B cell-depleting agents (E.g., rituximab), chimeric antigen receptor (CAR)-T cell therapies, or cytokine/integrin inhibitors. Patients receiving tyrosine kinase inhibitor (TKI ...

Indeed, selective depletion of B lymphocytes prevented the onset of autoimmune diabetes in these mice. Pescovitz was aware that rituximab—a chimeric anti-CD20 monoclonal antibody developed to ...